These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1575981)

  • 1. A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test.
    Bosman B; Matthiesen T; Hess V; Friderichs E
    Skin Pharmacol; 1992; 5(1):41-8. PubMed ID: 1575981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis.
    Sebök B; Bonnekoh B; Kerényi M; Gollnick H
    Skin Pharmacol Appl Skin Physiol; 2000; 13(5):285-91. PubMed ID: 10940819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dithranol and a 'synthetic tar' as anti-psoriatic treatments using the mouse tail test.
    Wrench R; Britten AZ
    Br J Dermatol; 1975 Jul; 93(1):75-8. PubMed ID: 1191531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fumaric acid, its dimethylester, and topical antipsoriatic drugs on epidermal differentiation in the mouse tail model.
    Sebök B; Szabados T; Kerényi M; Schneider I; Mahrle G
    Skin Pharmacol; 1996; 9(2):99-103. PubMed ID: 8722603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model.
    Bhatia A; Singh B; Wadhwa S; Raza K; Katare OP
    Pharm Dev Technol; 2014 Mar; 19(2):160-3. PubMed ID: 23369039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a therapeutic concentration of dithranol in the mouse-tail test.
    Hofbauer M; Dowd PM; Atkinson J; Whitefield M; Greaves MW
    Br J Dermatol; 1988 Jan; 118(1):85-9. PubMed ID: 3342179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tar treatment of psoriasis].
    Goerz G; Merk H; Hölzle E
    Hautarzt; 1985 Jan; 36(1):50-3. PubMed ID: 3972580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis.
    Bosman B
    Skin Pharmacol; 1994; 7(6):324-34. PubMed ID: 7946375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of psoriasis with salicylic acid, tar and dithranol].
    Juhlin L
    Lakartidningen; 1979 Oct; 76(43):3758-9. PubMed ID: 529922
    [No Abstract]   [Full Text] [Related]  

  • 10. Tars and anthralins.
    Silverman A; Menter A; Hairston JL
    Dermatol Clin; 1995 Oct; 13(4):817-33. PubMed ID: 8785886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone).
    Mustakallio KK; Brandt H
    Acta Derm Venereol; 1984; 64(1):63-6. PubMed ID: 6203285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center.
    Dutz JP; Lui H
    Int J Dermatol; 1998 Jan; 37(1):51-3. PubMed ID: 9522242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis.
    Dhanabal SP; Priyanka Dwarampudi L; Muruganantham N; Vadivelan R
    Phytother Res; 2012 Apr; 26(4):617-9. PubMed ID: 21915932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis: a review. II.
    Baker H
    Dermatologica; 1975; 150(3):136-53. PubMed ID: 1098945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). II. Clinical comparison of dithranol and butantrone sticks with special reference to side effects.
    Brandt H
    Acta Derm Venereol; 1987; 67(1):55-61. PubMed ID: 2436415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay.
    Pol A; Bergers M; Schalkwijk J
    In Vitro Cell Dev Biol Anim; 2003; 39(1-2):36-42. PubMed ID: 12892525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal activity of NAD-dependent isocitrate dehydrogenase in psoriasis during treatment with dithranol.
    Hammar H
    J Invest Dermatol; 1975 Sep; 65(3):315-9. PubMed ID: 169306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes.
    Raza K; Katare OP; Setia A; Bhatia A; Singh B
    J Microencapsul; 2013; 30(3):225-36. PubMed ID: 23088318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy.
    Swinkels OQ; Prins M; Tosserams EF; Gerritsen MJ; Van Der Valk PG; Van De Kerkhof PC
    Br J Dermatol; 2001 Jul; 145(1):63-9. PubMed ID: 11453908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Topical Celecoxib as an Anti-Psoriasis Agent.
    Nitescu DA; Paunescu H; Gologan D; Mihai A; Stoian AC; Coman OA
    Maedica (Bucur); 2022 Dec; 17(4):805-811. PubMed ID: 36818260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.